Nexpoint Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-656,380
Closed -$75.9M 101
2023
Q3
$75.9M Buy
656,380
+74,433
+13% +$8M 10.38% 3
2023
Q2
$59.9M Sell
581,947
-63,351
-10% -$6.68M 8.73% 2
2023
Q1
$70.4M Buy
645,298
+133,000
+26% +$14.7M 7.62% 5
2022
Q4
$58.3M Buy
+512,298
New +$42.6M 4.54% 7
2022
Q1
Sell
-6,200
Closed -$668K 247
2021
Q4
$668K Buy
+6,200
New +$676K 0.09% 114

Other funds holding HZNP

Nexpoint Asset Management's HZNP Position: Q4 2023 in Review

Nexpoint Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 656,380 shares — an estimated $75.9M sold.

Nexpoint Asset Management first reported a position in HZNP in Q4 2021 and held it in 5 quarters. The position peaked at $75.9M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Nexpoint Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Nexpoint Asset Management sold 656,380 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $75.9M.
  • Nexpoint Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 5 quarters.
  • Nexpoint Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $75.9M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Nexpoint Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.